NCT00929396已完成1 期
A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)Administered in PPD Positive Volunteers at 0 and 2 Months
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Physical examination. Local adverse events.Systemic adverse events. Laboratory safety tests including urine safety tests.
研究概览
简要总结
The purpose of this study is to evaluate the safety profile of an adjuvanted TB subunit vaccine administered at 0 and 2 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female between 18 and 55 years old
- •BCG group: Known to be BCG-vaccinated over 2 years before, PPD positive (range 6-15 mm or any documented value between 6-15 mm on medical file in the past), with no active, chronic or past TB disease as confirmed by chest X ray, negative QuantiFERON-TB Gold In Tube test and negative 6-day lymphocyte tests.
- •Infection group: Known to be treated for latent TB, PPDpositive (equal or over 10 mm or documented equal or over 10 mm positive on medical file in the past), previously TB infected but with no active disease confirmed by chest X ray, may have received chemoprophylaxis but with no TB treatment/chemoprophylaxis within the preceding 2 years, positive QuantiFERON-TB Gold In Tube test and/or positive 6-day lymphocyte test.
- •Healthy based on medical examination/history at the inclusion
- •Signed informed consent
- •Prepared to grant authorized persons access to the medical records
- •The volunteer is likely to comply with instructions
排除标准
- •Granulomatous disease (by chest X-ray)
- •Vaccinated with live vaccine 3 months before first vaccination
- •Administration of immune modulating drugs (steroids, immunosuppressive drugs or immunoglobulins) 3 months before the first vaccination
- •HBV, HCV or HIV sero-positive
- •Participation in other clinical trials
- •Known hypersensitivity to any of the vaccine components
- •Laboratory parameters outside of normal range judged by PI to be clinically relevant
- •Pregnant women/planned pregnancy and/or breastfeeding within the trial period
结局指标
主要结局
Physical examination. Local adverse events.Systemic adverse events. Laboratory safety tests including urine safety tests.
时间窗: From first vaccination until 8 months after the first vaccination
次要结局
- Detection by ELISPOT of IFNgamma spot-forming cells in PBMCs. Detection by ELISA of IFNgamma production in supernatants of PBMC. Detection by ELISA of IgG antibodies in serum/plasma. Detection by Elisa of TNFalfa and IFNgamma in serum(From first vaccination until 8 months after first vaccination)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit VaccineTuberculosisNCT01003093Statens Serum Institut36
已完成
1 期
A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85ATuberculosisNCT00653770University of Oxford31
已完成
1 期
Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal RouteTuberculosisNCT01497769University of Oxford24
已完成
1 期
A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIVTuberculosisNCT00731471University of Oxford24
终止
1 期
Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis VaccineTuberculosisNCT00800670McMaster University24